title: MenHibrix: a new combination meningococcal vaccine for infants and toddlers.
abstract: OBJECTIVE
  To review the immunogenicity and safety of the Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (Hib-MenCY-TT) for infants and toddlers.
  
  
  METHODS
  Studies conducted in humans and limited to publication in English were identified through a MEDLINE (January 2000 to September 2013) search using the terms Hib-MenCY-TT, MenHibrix, and Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine. Clinical trial registries, Web sites, and reference citations from publications identified were reviewed for additional sources.
  
  
  METHODS
  Randomized controlled trials were included to evaluate the safety and immunogenicity of Hib-MenCY-TT. Epidemiological data and recommendations from the Advisory Committee on Immunization Practices (ACIP) were also reviewed.
  
  
  RESULTS
  Hib-MenCY-TT is available for primary vaccination of infants as a 4-dose series at 2, 4, 6, and 12 to 15 months of age. Hib-MenCY-TT has comparable immunogenicity to licensed Hib vaccines and produces high levels of N meningitidis antibodies against serogroups C and Y. The most common adverse events were pain and redness at the injection site, drowsiness, and irritability.
  
  
  CONCLUSIONS
  Hib-MenCY-TT has been demonstrated to be a safe and immunogenic vaccination for prevention of disease caused by N meningitidis serogroups C and Y and H influenzae type b in healthy infants and toddlers. Currently, the ACIP recommends the use of Hib-MenCY-TT specifically in high-risk infants aged 6 weeks to 18 months. Hib-MenCY-TT provides the first therapeutic option for vaccination of infants as young as 6 weeks of age who are at increased risk for meningococcal disease.
authors.affiliation: Geisinger Health System, Danville, PA, USA.
authors.forename: Sarah F
authors.initials: SF
authors.lastname: Hale
authors.forename: Lauren
authors.initials: L
authors.lastname: Camaione
authors.forename: Ben M
authors.initials: BM
authors.lastname: Lomaestro
mesh_terms: D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D018073:Haemophilus Vaccines / Q000276:immunology* / Q000494:pharmacology; D006801:Humans; D007223:Infant; D008583:Meningitis, Haemophilus / Q000276:immunology / Q000517:prevention & control*; D008585:Meningitis, Meningococcal / Q000276:immunology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000276:immunology* / Q000494:pharmacology; D011135:Polysaccharides, Bacterial / Q000276:immunology* / Q000494:pharmacology; D013745:Tetanus Toxoid / Q000276:immunology* / Q000494:pharmacology; D014611:Vaccination; D018074:Vaccines, Conjugate
chemical_list: D018073:Haemophilus Vaccines; C527605:Hib-MenCY-TT vaccine; D022401:Meningococcal Vaccines; D011135:Polysaccharides, Bacterial; D013745:Tetanus Toxoid; D018074:Vaccines, Conjugate
keywords: Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine; Hib-MenCY-TT; MenHibrix; immunization; vaccine